NASDAQ:AMGN

Amgen (AMGN) Stock Forecast, Price & News

$266.54

-2.22 (-0.83%)

(As of 11:16 AM ET)

Compare

Today's Range: $265.39
▼
$268.49
50-Day Range: $230.41
▼
$271.46
52-Week Range: $211.71
▼
$296.67

Volume: 491,900 shs
Average Volume: 2.44 million shs
Market Capitalization: $142.57 billion

P/E Ratio: 17.97
Dividend Yield: 3.20%
Price Target: $265.44

Amgen MarketRank™ Forecast

Analyst Rating: Hold
2.40 Rating Score
Upside/Downside: 0.5% Downside
$265.44 Price Target
Short Interest: Healthy
1.17% of Float Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -2.42
Upright™ Environmental Score
News Sentiment: 1.03
Based on 14 Articles This Week
Insider Trading: Acquiring Shares
$30 M Bought Last Quarter
Proj. Earnings Growth: 8.61%
From $18.35 to $19.93 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.88 out of 5 stars

Medical Sector

51st out of 969 stocks

Biological Products, Except Diagnostic Industry

5th out of 161 stocks

2.2

Analyst's Opinion

Consensus Rating
Amgen has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 8 buy ratings, 5 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $265.44, Amgen has a forecasted downside of 0.5% from its current price of $266.77.
Amount of Analyst Coverage
Amgen has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
1.17% of the float of Amgen has been sold short.
Short Interest Ratio / Days to Cover
Amgen has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Amgen has recently increased by 1.13%, indicating that investor sentiment is decreasing.

4.2

Dividend Strength

Dividend Yield
Amgen pays a meaningful dividend of 3.17%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Amgen has been increasing its dividend for 11 years.
Dividend Coverage
The dividend payout ratio of Amgen is 57.45%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Amgen will have a dividend payout ratio of 42.75% next year. This indicates that Amgen will be able to sustain or increase its dividend.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Amgen has received a 53.36% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Denosumab", "Etanercept", "Darbepoetin alfa", and "Apremilast" products. See details.
Environmental Sustainability
The Environmental Impact score for Amgen is -2.42.

2.8

News and Social Media Coverage

News Sentiment
Amgen has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 14 news articles for Amgen this week, compared to 15 articles on an average week.
Search Interest
Only 38 people have searched for AMGN on MarketBeat in the last 30 days. This is a decrease of -16% compared to the previous 30 days.
MarketBeat Follows
42 people have added Amgen to their MarketBeat watchlist in the last 30 days. This is an increase of 62% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Amgen insiders have bought 1,096.03% more of their company's stock than they have sold. Specifically, they have bought $29,999,985.00 in company stock and sold $2,508,306.00 in company stock.
Percentage Held by Insiders
Only 0.57% of the stock of Amgen is held by insiders.
Percentage Held by Institutions
74.44% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Amgen are expected to grow by 8.61% in the coming year, from $18.35 to $19.93 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Amgen is 17.99, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 110.43.
Price to Earnings Ratio vs. Sector
The P/E ratio of Amgen is 17.99, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 97.21.
Price to Earnings Growth Ratio
Amgen has a PEG Ratio of 3.38. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Amgen has a P/B Ratio of 38.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Amgen (NASDAQ:AMGN) Stock

Amgen Inc. is a multinational biopharmaceutical company headquartered in Thousand Oaks, California. Established in 1980 by William Bowes from Cetus Corporation and Winston Salser from UCLA, Amgen is now one of the world's largest independent biotechnology companies, with over 24,000 employees worldwide. The company's primary focus is on molecular biology and biochemistry, intending to provide healthcare solutions based on recombinant DNA technology.

Neulasta, one of Amgen's most prominent selling product lines, is used to prevent infections in patients undergoing cancer chemotherapy. Enbrel is another famous selling product line for Amgen, used in the treatment of rheumatoid arthritis and other autoimmune diseases. The company's other products have various applications in treating cancer, anemia, osteoporosis and other conditions.

Amgen has a rich history of strong leadership, with the appointment of several successful CEOs since its inception. Robert A. Bradway is the current CEO and was brought to Amgen in May 2012 following his predecessor's retirement. Bradway has led the company to new heights with strategic acquisitions and partnerships.

Amgen has made at least five major corporate acquisitions. In 2019, the company announced it would acquire Nuevolution AB and the Otezla drug program from Celgene and a 20.5% stake in the Beijing-based BeiGene for $2.7 billion. These acquisitions have strengthened Amgen's drug pipeline and provided new revenue streams for the company. In March 2021, Amgen announced its plans to acquire Five Prime Therapeutics and its lead research drug candidate, bemarituzumab, for $1.9 billion. It also agreed to acquire Rodeo Therapeutics for up to $720 million. These acquisitions are part of the company's ongoing efforts to expand its drug pipeline and bring new treatments to patients.

In 2012, Amgen faced legal issues when it pleaded guilty and agreed to pay $150 million in criminal penalties and $612 million in damages to resolve 11 related whistleblower complaints. Amgen has also faced criticism for lobbying for a two-year extension on sales of drugs, including Sensipar, without government controls, which will cost taxpayers an estimated $500 million. However, the company remains committed to providing innovative and effective healthcare solutions for patients.

Amgen's success can be attributed to its commitment to innovation, strategic acquisitions, strong partnerships and top-end leadership. The company's impressive portfolio of products and its commitment to the community has solidified Amgen's position as a leader in biopharmaceuticals.

AMGN Price History

30 days | 90 days | 365 days | Advanced Chart

AMGN Stock News Headlines

September 25, 2023 | marketbeat.com

Argenx's 28% Surge & Promising Product Propel Investor Confidence (AMGN)

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

September 20, 2023 | marketbeat.com

Flee to Healthcare Stocks if Recession Rears its Head? (AMGN)

In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.

October 2, 2023 | Edge On The Street (Ad)

Gold Could Be Heading for Record Highs - But How to Play It?

According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.

September 6, 2023 | marketbeat.com

3 Growth Stocks to Buy in September (AMGN)

As the calendar turns to September, optimistic investors will look for value in quality companies with a history of generating strong revenue and earnings

September 30, 2023 | msn.com

Amgen Stock Was a Winner in the Third Quarter. These Solar Shares Weren't.

September 28, 2023 | markets.businessinsider.com

DBS Remains a Buy on Amgen (AMGN)

September 27, 2023 | proactiveinvestors.com

Neumora Therapeutics stock surges as Amgen confirmed as major shareholder

September 27, 2023 | finance.yahoo.com

Amgen Could Get a Piece of the Obesity Market

October 2, 2023 | PressReach (Ad)

Nuclear Revival Creates Opportunities for Uranium

Uranium companies set to benefit from increased demand for clean energy.

September 25, 2023 | markets.businessinsider.com

FDA Strikes Off Coherus BioSciences' New Injector Biosimilar Treatment For Cancer Patients

September 25, 2023 | finance.yahoo.com

Dow Jones Biotech Giant Amgen, Meta Stock, Eye Buy Points In Stock Market Correction

September 23, 2023 | finance.yahoo.com

The Hedge Fund That Made a Killing Betting Against Lina Khan

September 21, 2023 | finance.yahoo.com

Amgen (AMGN) Stock Moves -0.76%: What You Should Know

September 21, 2023 | finance.yahoo.com

Why Shares of Neumora Therapeutics Slumped This Week

September 20, 2023 | finance.yahoo.com

AMGEN LAUNCHES PARTNERS OF CHOICE NETWORK OF EIGHT LEADING ONCOLOGY ACADEMIC CENTERS

September 20, 2023 | finance.yahoo.com

Amgen (AMGN)'s True Worth: A Complete Analysis of Its Market Value

September 20, 2023 | msn.com

IBM, Amgen share gains contribute to Dow's nearly 200-point jump

September 20, 2023 | msn.com

Dow's nearly 100-point rally led by gains for shares of Amgen, IBM

September 20, 2023 | finance.yahoo.com

Best Dividend Stocks: Amgen Hits Buy Point, Offers Solid Dividend Growth

September 19, 2023 | finance.yahoo.com

FTC chair targets deals that have fallen in agency's 'blind spots'

September 19, 2023 | finance.yahoo.com

Healthcare: FTC Chair Lina Khan to crack down on 'below radar' deals

September 15, 2023 | benzinga.com

Amgen Unusual Options Activity

September 14, 2023 | stocknews.com

Moderna (MRNA) Stock Analysis: Is the Biotech Stock a Buy at This Time?

September 14, 2023 | investing.com

Nvidia, Amgen back AI-driven drug firm Generate:Biomedicines' $273 million fundraise

September 14, 2023 | finance.yahoo.com

Amgen-partnered AI biotech startup brings in $273M

September 14, 2023 | finance.yahoo.com

Nvidia, Amgen back AI-driven drug firm Generate:Biomedicines' $273 mln fundraise

September 14, 2023 | finance.yahoo.com

Should You Consider Selling Amgen (AMGN)?

See More Headlines

Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

AMGN Company Calendar

Last Earnings: 8/03/2023
Ex-Dividend for 9/8 Dividend: 8/17/2023
Dividend Payable: 9/08/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:AMGN
CUSIP: 03116210
CIK: 318154
Web: www.amgen.com
Phone: (805) 447-1000
Fax: 805-447-1010
Employees: 25,200
Year Founded: 1980

Price Target and Rating

Average Stock Price Forecast: $265.44
High Stock Price Forecast: $320.00
Low Stock Price Forecast: $200.00
Forecasted Upside/Downside: -1.2%
Consensus Rating: Hold
Rating Score (0-4): 2.40
Research Coverage: 15 Analysts

Profitability

EPS (Most Recent Fiscal Year): $14.83
Trailing P/E Ratio: 18.12
Forward P/E Ratio: 14.65
P/E Growth: 3.38
Net Income: $6.55 billion
Net Margins: 30.02%
Pretax Margin: 34.60%
Return on Equity: 196.60%
Return on Assets: 12.42%

Debt

Debt-to-Equity Ratio: 8.76
Current Ratio: 2.77
Quick Ratio: 2.48

Sales & Book Value

Annual Sales: $26.32 billion
Price / Sales: 5.46
Cash Flow: $24.34 per share
Price / Cash Flow: 11.04
Book Value: $6.86 per share
Price / Book: 39.18

Miscellaneous

Outstanding Shares: 534,900,000
Free Float: 532,440,000
Market Cap: $143.76 billion
Optionable: Optionable
Beta: 0.61

Social Links

10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Robert A. Bradway (Age 60)
Chairman, CEO & Pres
Comp: $5.49M

Mr. Peter H. Griffith (Age 64)
Exec. VP & CFO
Comp: $2.57M

Mr. Esteban Santos (Age 55)
Exec. VP of Operations
Comp: $2.52M

Dr. David M. Reese M.D. (Age 60)
Exec. VP of R&D
Comp: $2.83M

Mr. Murdo Gordon (Age 56)
Exec. VP of Global Commercial Operations
Comp: $2.72M

Mr. Matthew C. Busch (Age 49)
Chief Accounting Officer & VP of Fin.

Mr. Mike Zahigian
Sr. VP & Chief Information Officer

Mr. Arvind Sood
VP of Investor Relations

Mr. Jonathan P. Graham (Age 62)
Exec. VP, Gen. Counsel & Sec.

Ms. Nancy A. Grygiel (Age 55)
Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AMGN Stock - Frequently Asked Questions

Should I buy or sell Amgen stock right now?: 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View AMGN analyst ratings or view top-rated stocks.
What is Amgen's stock price forecast for 2023?: 15 Wall Street analysts have issued 1 year target prices for Amgen's shares. Their AMGN share price forecasts range from $200.00 to $320.00. On average, they expect the company's stock price to reach $265.44 in the next twelve months. This suggests that the stock has a possible downside of 1.2%.
View analysts price targets for AMGN or view top-rated stocks among Wall Street analysts.
How have AMGN shares performed in 2023?: Amgen's stock was trading at $262.64 at the beginning of 2023. Since then, AMGN shares have increased by 2.3% and is now trading at $268.76.
View the best growth stocks for 2023 here.
When is Amgen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our AMGN earnings forecast.
How were Amgen's earnings last quarter?: Amgen Inc. (NASDAQ:AMGN) announced its quarterly earnings data on Thursday, August, 3rd. The medical research company reported $5.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.44 by $0.56. The medical research company had revenue of $7 billion for the quarter, compared to analysts' expectations of $6.66 billion. Amgen had a trailing twelve-month return on equity of 196.60% and a net margin of 30.02%. The company's revenue was up 6.2% compared to the same quarter last year. During the same period last year, the firm earned $4.65 EPS.
Read the conference call transcript.
How often does Amgen pay dividends? What is the dividend yield for Amgen?: Amgen announced a quarterly dividend on Tuesday, August 1st. Investors of record on Friday, August 18th will be paid a dividend of $2.13 per share on Friday, September 8th. This represents a $8.52 annualized dividend and a yield of 3.17%. The ex-dividend date is Thursday, August 17th.
Read our dividend analysis for AMGN.
What ETFs hold Amgen's stock?: ETFs with the largest weight of Amgen (NASDAQ:AMGN) stock in their portfolio include Timothy Plan Market Neutral ETF (TPMN), VanEck Biotech ETF (BBH), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Pharmaceuticals ETF (PJP), FT Cboe Vest DJIA Dogs 10 Target Income ETF (DOGG) and Invesco Dow Jones Industrial Average Dividend ETF (DJD).
Is Amgen a good dividend stock?: Amgen (NASDAQ:AMGN) pays an annual dividend of $8.52 per share and currently has a dividend yield of 3.17%. The company has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 57.45%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AMGN will have a dividend payout ratio of 42.75% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AMGN.

What guidance has Amgen issued on next quarter's earnings?: Amgen updated its FY23 earnings guidance on Thursday, August, 3rd. The company provided earnings per share (EPS) guidance of $17.80-$18.80 for the period, compared to the consensus estimate of $17.73. The company issued revenue guidance of $26.6-$27.4 billion, compared to the consensus revenue estimate of $27.02 billion.
What is Robert A. Bradway's approval rating as Amgen's CEO?: 1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend.
What other stocks do shareholders of Amgen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).
What is Amgen's stock symbol?: Amgen trades on the NASDAQ under the ticker symbol "AMGN."
How do I buy shares of Amgen?: Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Amgen's stock price today?: One share of AMGN stock can currently be purchased for approximately $268.76.
How much money does Amgen make?: Amgen (NASDAQ:AMGN) has a market capitalization of $143.76 billion and generates $26.32 billion in revenue each year. The medical research company earns $6.55 billion in net income (profit) each year or $14.83 on an earnings per share basis.
How many employees does Amgen have?: The company employs 25,200 workers across the globe.
Does Amgen have any subsidiaries?: The following companies are subsidiares of Amgen: Abgenix, Alantos Pharmaceuticals, Amgen Canada Inc., Amgen Europe GmbH, Amgen Fremont Inc., Amgen Global Finance B.V., Amgen GmbH Germany, Amgen Ilaç Ticaret Limited Şirketi, Amgen K-A Inc., Amgen Manufacturing Limited, Amgen Research Munich GmbH, Amgen Rockville Inc., Amgen S.A., Amgen S.A.S., Amgen S.p.A., Amgen SF LLC, Amgen Singapore Manufacturing Pte. Ltd., Amgen Technology Ireland Unlimited Company, Amgen Technology Limited, Amgen USA Inc., Amgen Worldwide Holdings B.V., Avidia, Bergamo, BioVex, BioVex Inc., Catherex, Catherex, DeCODE Genetics, Dezima Pharma, Filgrastim and Pegfilgrastim, Five Prime Therapeutics, Five Prime Therapeutics Inc., Gensenta İlaç Sanayi ve Ticaret Anonim Şirketi, Ilypsa, Immunex, Immunex Corporation, Immunex Rhode Island Corporation, KAI Pharmaceuticals, KAI Pharmaceuticals Inc., Kinetix Pharmaceuticals, Laboratorio Quimico Farmaceutico Bergamo, MN Pharmaceuticals, Micromet, Nuevolution, Onyx Pharmaceuticals, Onyx Pharmaceuticals Inc., Onyx Therapeutics Inc., Otezla, Rodeo Therapeutics, Saga Investments Coöperatief U.A., Synergen, TeneoBio, TeneoBio Inc., Tularik, deCODE Genetics ehf, and llypsa Inc..
Read More
How can I contact Amgen?: Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The official website for the company is www.amgen.com. The medical research company can be reached via phone at (805) 447-1000, via email at investor.relations@amgen.com, or via fax at 805-447-1010.

This page (NASDAQ:AMGN) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Amgen (AMGN) Stock Forecast, Price & News

Amgen MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Amgen (NASDAQ:AMGN) Stock

AMGN Price History

AMGN Stock News Headlines

AMGN Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

AMGN Stock - Frequently Asked Questions

Overall MarketRank^™